Theranexus SA (ALTHX) Price & Analysis

Compare

6 Followers

ALTHX Stock Chart & Stats

€2.03

-€0.01(-2.06%)

At close: Jan 09 4:00 PM EST

€2.03

-€0.01(-2.06%)

Day’s Range― - ―

52-Week Range€0.25 - €5.10

Previous CloseN/A

Volume1.58K

Average Volume (3M)133.77K

Market Cap

€56.70M

Enterprise Value€40.97M

Total Cash (Recent Filing)€966.59K

Total Debt (Recent Filing)€2.87M

Price to Earnings (P/E)―

Beta0.24

Next Earnings

May 05, 2026

EPS EstimateN/A

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-0.14

Shares Outstanding13,796,556

10 Day Avg. Volume147,352

30 Day Avg. Volume133,766

Financial Highlights & Ratios

PEG Ratio0.04

Price to Book (P/B)-2.98

Price to Sales (P/S)2.16

P/FCF Ratio-1.45

Enterprise Value/Market CapN/A

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/EbitdaN/A

Forecast

1Y Price TargetN/A

Price Target UpsideN/A

Rating ConsensusN/A

Number of Analyst Covering0

EPS Forecast (FY)0.37

Revenue Forecast (FY)N/A

Bulls Say, Bears Say

Bulls Say

Focused CNS / Rare-disease PipelineTheranexus’ explicit focus on CNS disorders and rare neurological diseases targets areas of high unmet medical need and structural demand. A specialized pipeline can command premium pricing, attract partner interest, and sustain long-term strategic value if clinical progress continues.

Translational Neurobiology ExpertiseThe company’s emphasis on neurobiology and translational medicine is a durable scientific advantage: capabilities to bridge discovery to clinic reduce development risk, improve trial design, and increase attractiveness to collaborators or acquirers, supporting long-term program success probability.

Lean Organizational FootprintA very small headcount implies a lean cost structure and potential capital efficiency in early-stage development. Over several months this can extend runway versus larger fixed-cost peers and allow management to prioritize and fund key clinical milestones with lower overhead.

Bears Say

Declining Revenue With Negative MarginsSustained revenue decline and deeply negative gross, EBIT and net margins indicate structural inability to monetize operations and control costs. This reduces internal funding capacity for trials, increases reliance on external capital, and undermines long-term financial sustainability.

Balance Sheet Weakness And Negative EquityNegative equity and a distorted debt-to-equity ratio reflect capital deficits and credit strain. Over months this limits strategic flexibility, raises refinancing and covenant risks, and makes new financing more dilutive or costly, constraining growth and program funding options.

Persistent Negative Cash Flow And Worsening FCFOngoing negative operating and free cash flows, and a steeply worsening FCF growth rate, signal structural cash burn. Over a multi-month horizon this pressures liquidity, forces frequent external financing or dilution, and restricts the ability to invest in trials or commercial preparation.

Theranexus SA News

Theranexus Reports Semi-Annual Liquidity Contract Update

An update from Theranexus SA ( ($FR:ALTHX) ) is now available. Theranexus has released its semi-annual report for...

1y ago

Theranexus Strengthens Cash Position and Advances Drug Development Initiatives

Theranexus SA ( ($FR:ALTHX) ) has shared an update. Theranexus has reported a strengthened cash position of €4.0...

1y ago

Theranexus Announces 2025 Financial Communication Agenda

Theranexus SA ( ($FR:ALTHX) ) has issued an update. Theranexus has announced its financial communication agenda for 2025,...

1y ago

Theranexus Announces Share and Voting Rights Information

Theranexus SA ( ($FR:ALTHX) ) has provided an update. Theranexus has disclosed the total number of shares and...

1y ago

Theranexus Publishes Shareholder Letter, Reinforcing Commitment to Rare Neurological Treatments

The latest announcement is out from Theranexus SA ( ($FR:ALTHX) ). Theranexus has announced the publication of its...

1y ago

Theranexus Strengthens Financial Outlook with New Agreements

Theranexus SA (FR:ALTHX) has released an update. Theranexus SA announces a significant boost in its cash position following...

1y ago

Theranexus Reports Promising Trial Results for Batten-1

Theranexus SA (FR:ALTHX) has released an update. Theranexus, in collaboration with the Beyond Batten Disease Foundation, has announced...

1y ago

Theranexus Updates Cash Position and Strategic Focus

Theranexus SA (FR:ALTHX) has released an update. Theranexus reports a slight increase in cash reserves to €1.9 million...

1y ago

Theranexus Teams with Synerlab for Pediatric Miglustat

Theranexus SA (FR:ALTHX) has released an update. Theranexus partners with Synerlab to produce and commercialize its innovative pediatric...

1y ago

Theranexus Reports Profit and Reduced Expenses in H1 2024

Theranexus SA (FR:ALTHX) has released an update. Theranexus SA, a biopharmaceutical company, has reported a significant reduction in...

1y ago

ALTHX FAQ

What was Theranexus SA’s price range in the past 12 months?

Theranexus SA lowest stock price was €0.25 and its highest was €5.10 in the past 12 months.

What is Theranexus SA’s market cap?

Theranexus SA’s market cap is €56.70M.

When is Theranexus SA’s upcoming earnings report date?

Theranexus SA’s upcoming earnings report date is May 05, 2026 which is in 77 days.

How were Theranexus SA’s earnings last quarter?

Theranexus SA released its earnings results on Sep 25, 2025. The company reported -€0.138 earnings per share for the quarter, missing the consensus estimate of N/A by -€0.138.

Is Theranexus SA overvalued?

According to Wall Street analysts Theranexus SA’s price is currently Overvalued. Get more investment ideas with TipRanks Premium

Does Theranexus SA pay dividends?

Theranexus SA does not currently pay dividends.

What is Theranexus SA’s EPS estimate?

Theranexus SA’s EPS estimate for its next earnings report is not yet available.

How many shares outstanding does Theranexus SA have?

Theranexus SA has 13,796,556 shares outstanding.

What happened to Theranexus SA’s price movement after its last earnings report?

Theranexus SA reported an EPS of -€0.138 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went up 2.171%.

Which hedge fund is a major shareholder of Theranexus SA?

Currently, no hedge funds are holding shares in FR:ALTHX

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Company Description

Theranexus SA

Theranexus société anonyme, a biopharmaceutical company, develops drug candidates for the treatment of central nervous system disorders. The company's lead drug candidate is THN102, which is in Phase II clinical trial to treat sleep/wake disorders. It also develops THN201 for the treatment of neurocognitive disorders linked to Alzheimer's disease; and THN101 to treat neuropathic pain. The company was founded in 2013 and is based in Lyon, France.